Functional Concept – Page 28

Boehringer Ingelheim’s Nerandomilast Achieves Second Phase III Success in Pulmonary Fibrosis Treatment

5 months ago talkbio0Tagged Boehringer, FIBRONEER-ILD, Force, Idiopathic Pulmonary Fibrosis, Ingelheim, nerandomilast, Phase 3 Clinical Trials, Progressive, Pulmonary Fibrosis, Respiratory physiology, Vital capacity

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, lung function, forced vital capacity

Roivant’s Kinevant Discontinues Namilumab Development for Pulmonary Sarcoidosis After Phase 2 Failure

5 months ago talkbio0Tagged Drug Development, Failure (biologic function), Kinevant, namilumab, Phase 2 clinical trial, Roivant, Sarcoidosis, Pulmonary

Roivant Sciences, Kinevant, namilumab, pulmonary sarcoidosis, Phase 2 clinical trial, RESOLVE-Lung study, drug development failure

Boehringer Ingelheim’s Nerandomilast Succeeds in Second Phase III Lung Fibrosis Trial, Paving Way for FDA Approval

5 months ago talkbio0Tagged Approved, Boehringer, FIBRONEER-ILD, fibrosing, Improvement, Ingelheim, Inhibitor, nerandomilast, PF-ILDs, Phase 3 Clinical Trials, phosphodiesterase 4B, Progressive, Respiratory physiology, United States Food and Drug Administration

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive fibrosing interstitial lung diseases (PF-ILDs), lung function improvement, FDA approval, phosphodiesterase 4B (PDE4B) inhibitor

Sionna Therapeutics Raises $191M in Upsized IPO, Aardvark Therapeutics Aims for $100M Listing

5 months ago talkbio0Tagged biotech, Cystic Fibrosis, IPOs, Metabolic Diseases, Nasdaq, Obesity, Order Tubulidentata (organism)

Biotech IPOs, Sionna Therapeutics, Aardvark Therapeutics, Cystic Fibrosis, Metabolic Diseases, NASDAQ, Obesity Treatment

Illumina’s Double-Edged Sword: Navigating US-China Trade Tensions

5 months ago talkbio0Tagged BIOSECURE, China, DNA Sequence, Entity, Illumina, Industry, Tension, TNFRSF19 gene, unreliable

Illumina, China, tariffs, trade tensions, DNA sequencing, unreliable entity list, biotech industry, BIOSECURE Act

AstraZeneca Discontinues Vemircopan, Takes $753M Charge on Former Alexion Asset

5 months ago talkbio0Tagged Alexion, AstraZeneca, charge amounts, Complement Inactivating Agents, drug discontinuation, Drug Industry, Impaired, Vemircopan

AstraZeneca, Alexion, vemircopan, complement inhibitor, drug discontinuation, impairment charge, rare diseases, pharmaceutical industry

Novo Nordisk Projects Slower Growth for 2025, Targets CagriSema Approval in 2026

5 months ago talkbio0Tagged 2025, CagriSema, Drug Industry, Growth, Nordisk, Obesity, regulatory approval, Sales - occupational activity, Wegovy

Novo Nordisk, 2025 outlook, CagriSema, obesity treatment, pharmaceutical industry, Wegovy, sales growth, regulatory approval

FDA Halts Amgen’s Phase 1 Obesity Drug Trial: AMG 513 Study on Hold

5 months ago talkbio0Tagged AMG, amgen, Obesity, pharmaceutical setback, phase 1 trial, Study on Hold, United States Food and Drug Administration

Amgen, obesity drug, AMG 513, FDA clinical hold, Phase 1 trial, pharmaceutical setback

Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints

5 months ago talkbio0Tagged Arenaria, Biological Factors, clinical program, Discontinuation (procedure), Financial cost, Industry, Lymphocytes, Tumor-Infiltrating, Manufacturing, strategic alternatives, TIDAL-01

Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges

Metsera and Maze Therapeutics Raise $415 Million in Successful Biotech IPOs

5 months ago talkbio0Tagged biotech, Dosage Forms, IPOs, Kidney Diseases, Listings, Metsera, Nasdaq, Obesity

Biotech IPOs, Metsera, Maze Therapeutics, obesity treatment, kidney disease, NASDAQ listings, pharmaceutical funding